Lung Cancer Management

metrics 2024

Pioneering Insights in Oncology and Respiratory Medicine

Introduction

Lung Cancer Management, published by FUTURE MEDICINE LTD, is a premier academic journal dedicated to the evolving field of oncology and respiratory medicine. With an ISSN of 1758-1966 and an E-ISSN of 1758-1974, this journal offers a platform for the dissemination of cutting-edge research, clinical studies, and expert reviews, all focusing on the latest advances in lung cancer treatment and management. Despite being a relatively new entry since its inception in 2014 and achieving its converged years from 2020 to 2024, it has already established itself in the Q3 quartile for both oncology and pulmonary and respiratory medicine as of 2023, according to category quartiles rankings. With a Scopus ranking of #98 in the category of Pulmonary and Respiratory Medicine and #266 in Oncology, the journal reflects a commitment to quality and relevance in its content. Although it does not offer open access, it remains a crucial resource for researchers, clinicians, and students seeking to stay informed about the latest developments and practical approaches in lung cancer management. The journal is accessible from its base in the United Kingdom, at UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ensuring that it caters to a global audience eager to explore and contribute to this vital field of medicine.

Metrics 2024

SCIMAGO Journal Rank0.50
Journal Impact Factor0.90
Journal Impact Factor (5 years)2.70
H-Index5
Journal IF Without Self0.90
Eigen Factor0.00
Normal Eigen Factor0.05
Influence0.72
Immediacy Index0.10
Cited Half Life4.60
Citing Half Life6.40
JCI0.32
Total Documents32
WOS Total Citations161
SCIMAGO Total Citations60
SCIMAGO SELF Citations0
Scopus Journal Rank0.50
Cites / Document (2 Years)0.73
Cites / Document (3 Years)1.29
Cites / Document (4 Years)1.29

Metrics History

Rank 2024

Scopus

Pulmonary and Respiratory Medicine in Medicine
Rank #98/155
Percentile 36.77
Quartile Q3
Oncology in Medicine
Rank #266/404
Percentile 34.16
Quartile Q3

IF (Web Of Science)

RESPIRATORY SYSTEM
Rank 87/100
Percentile 13.50
Quartile Q4

JCI (Web Of Science)

RESPIRATORY SYSTEM
Rank 78/101
Percentile 22.77
Quartile Q4

Quartile History

Similar Journals

Clinical Genitourinary Cancer

Transforming insights into clinical practice.
Publisher: CIG MEDIA GROUP, LPISSN: 1558-7673Frequency: 6 issues/year

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

EUROPEAN RESPIRATORY JOURNAL

Exploring Innovations in Respiratory Research
Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTDISSN: 0903-1936Frequency: 12 issues/year

The EUROPEAN RESPIRATORY JOURNAL, published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, is at the forefront of advancing knowledge in the fields of pulmonary and respiratory medicine. With its ISSN 0903-1936 and E-ISSN 1399-3003, this esteemed journal has established itself as a leading platform since its inception in 1988, currently converging towards 2024. Ranked in the Q1 category for both Medicine (miscellaneous) and Pulmonary and Respiratory Medicine in 2023, it stands as the 3rd of 155 journals in its field, reflecting an impressive 98th percentile Scopus ranking. The journal boasts a rigorous selection of peer-reviewed articles that encompass innovative research, clinical studies, and reviews, thereby enhancing the understanding and treatment of respiratory diseases. Although it does not currently offer an Open Access option, the journal remains crucial for researchers, clinicians, and healthcare professionals committed to improving respiratory health across Europe and beyond. Join a community dedicated to groundbreaking research and advancements in respiratory medicine.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Exploring groundbreaking discoveries in cancer treatment.
Publisher: OXFORD UNIV PRESSISSN: 0368-2811Frequency: 12 issues/year

The Japanese Journal of Clinical Oncology, published by Oxford University Press, is a pivotal platform for advancing knowledge in the fields of cancer research, oncology, and related medical disciplines. Since its inception in 1971, this journal has contributed significantly to the dissemination of cutting-edge research and clinical practices, featuring a breadth of scholarly articles that cater to the needs of researchers, practitioners, and students alike. With an impact factor reflecting its robust reputation, the journal is ranked in the Q3 category for both Cancer Research and Oncology, and Q2 in Medicine (miscellaneous), and Radiology, Nuclear Medicine and Imaging as of 2023. These rankings, alongside the journal's Scopus rankings, signify its important role in the scientific community and its commitment to fostering innovative research. Although it is not an Open Access journal, the Japanese Journal of Clinical Oncology continues to provide valuable insights and educational resources, making it essential for anyone engaged in the fight against cancer.

Translational Lung Cancer Research

Elevating the standards of translational oncology research.
Publisher: AME PUBLISHING COMPANYISSN: 2218-6751Frequency: 6 issues/year

Translational Lung Cancer Research is a leading journal dedicated to advancing the field of oncology, particularly focusing on groundbreaking discoveries in lung cancer treatment and management. Published by AME Publishing Company, this journal boasts an impressive Q1 classification in the 2023 Oncology category, reflecting its significant contribution to the scientific community, with an outstanding Scopus rank of #92 out of 404 in Medicine _ Oncology, placing it in the 77th percentile. With its commitment to open access, the journal fosters international collaboration and accessibility, making cutting-edge research available to a wide audience. The scope of Translational Lung Cancer Research encompasses clinical trials, experimental studies, and translational research that bridge the gap between laboratory findings and clinical applications. Researchers, professionals, and students seeking to keep abreast of the latest developments in lung cancer research will find invaluable insights within its pages. For further information, please contact at FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG.

Current Problems in Cancer: Case Reports

Fostering collaboration to tackle oncology's toughest challenges.
Publisher: ELSEVIERISSN: 2666-6219Frequency: 2 issues/year

Current Problems in Cancer: Case Reports is a prominent scholarly journal published by Elsevier, focusing on critical case reports within the field of oncology. Since its transition to Open Access in 2020, it has enhanced accessibility for researchers and healthcare professionals seeking to share and discuss unique clinical scenarios and insights that advance cancer treatment and patient care. Operating from the United States, this journal aims to address the important and often intricate challenges faced in oncology, facilitating a platform for knowledge exchange and the exploration of new perspectives in cancer management. Despite its current Q4 category ranking in the 2023 oncology category of Scopus with a rank of #359/404, its goal is to enrich the academic discourse by featuring diverse case reports and promoting evidence-based practices. As the journal evolves from 2021 to 2024, it seeks to impact the field by inviting researchers, professionals, and students to contribute their findings, ultimately fostering a collaborative environment for tackling the complexities of cancer.

JTO Clinical and Research Reports

Pioneering Excellence in Clinical and Research Insights
Publisher: ELSEVIERISSN: Frequency: 12 issues/year

JTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.

Cancer Management and Research

Connecting researchers to redefine cancer care.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1322Frequency: 1 issue/year

Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.

Bladder Cancer

Advancing bladder cancer research for a healthier tomorrow.
Publisher: IOS PRESSISSN: 2352-3727Frequency: 4 issues/year

Bladder Cancer, published by IOS PRESS, is a premier open access journal dedicated to advancing the field of oncology and urology, with a specific focus on bladder cancer research and treatment. Established in 2015 and continuing through to 2024, this journal aims to disseminate high-quality, peer-reviewed research that contributes to the understanding, diagnosis, and management of bladder cancer, a critical area of concern in urological oncology. With a robust publication record now encompassing open access since 2023, Bladder Cancer ensures accessibility to vital research for clinicians, researchers, and scholars worldwide. The journal's rankings in Scopus reflect its commitment to excellence, holding a Q3 category in both oncology and urology, with Scopus ranks of #78 in Urology and #285 in Oncology, showcasing its growing influence in the scientific community. By fostering dialogue and innovation, Bladder Cancer serves as an essential resource for those committed to improving patient outcomes in bladder oncology.

Tuberculosis and Respiratory Diseases

Championing open access for global health insights.
Publisher: THE KOREAN ACAD TUBERCULOSIS & RESPIRATORY DISEASESISSN: 1738-3536Frequency: 4 issues/year

Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.

Pulmonary Medicine

Championing Open Access for Global Health Solutions
Publisher: HINDAWI LTDISSN: 2090-1836Frequency: 1 issue/year

Pulmonary Medicine, published by HINDAWI LTD, stands as a prestigious open-access journal since 2010, dedicated to advancing the field of pulmonary and respiratory medicine. Located in Egypt, this journal is indexed with an ISSN of 2090-1836 and an E-ISSN of 2090-1844, and it has attained a commendable Q2 ranking in both the miscellaneous medicine and pulmonary health categories, indicative of its significant impact and quality. With an impressive Scopus ranking of #15 out of 155 in the pulmonary and respiratory medicine category, the journal is positioned in the 90th percentile, highlighting its relevance and contribution to ongoing research. The journal aims to publish high-quality original research, reviews, and clinical studies that address pressing issues in pulmonary health, making it a vital resource for researchers, clinicians, and students seeking to enhance their understanding and practice in respiratory medicine. By embracing an open-access model, Pulmonary Medicine provides a platform for disseminating knowledge, fostering collaboration, and driving innovation within the global scientific community.